New Zealand to Conduct LSD Micro-Dosing Trial Targeting Cancer Patients

Researchers in New Zealand plan to run an LSD micro-dosing trial with patients in the advanced stages of cancer in an attempt to see whether the drug will improve their quality of life. The trial will be led by University of Auckland’s director of the postgraduate diploma in health psychology, Dr. Lisa Reynolds.

In an interview with a popular radio station, Reynolds stated that thus far, research had shown that psychedelic substances such as LSD possessed the potential to increase spirituality, decrease depression and anxiety, decrease the fear of death, and improve an individual’s quality of life. The objective of this new study is to find out whether micro-dosing LSD holds similar benefits to macro doses, which have demonstrated their ability to substantially reduce psychological distress in late-stage cancer patients.

While macro doses may also result in bad trips, micro-doses do not cause altered perceptions. The participants of the trial will be classified into two groups. Some of the trial’s participants will self-administer LSD once every three days, with Reynolds adding that while individuals may feel more creative, feel like their mood has improved or experience sensations of thinking more clearly, they won’t be tripping.

The other group of participants will take a placebo instead of the psychedelic. Reynolds notes that some of the effects induced by LSD can also be induced by a placebo, so it will be interesting to observe whether or not micro-doses of LSD will give rise to any additional effects.

The trial’s findings will help inform the development of an even bigger trial and offer a preliminary indication of the possible benefits of micro-dosing psychedelics in advanced cancer patients.

The university had revealed in May 2021 that they would be conducting the trial. Concurrently, a company based in Toronto that is working on developing psychedelic drugs for various indications, Mind Medicine (“MindMed”) Inc. (NASDAQ: MNMD) (NEO: MMED), also announced that they would be conducting a study that would focus on the use and benefits of LSD in treating pain.

The company’s chief development officer Rob Barrow stated that while evidence from the ’50s suggests that psychedelics such as LSD possessed analgesic effects, the treatment area remained untapped by companies that were researching psychedelics because most of the research focused mainly on psychiatric indications.

In addition to this, the company will also be carrying out a study in collaboration with the Maastricht University in the Netherlands, which will also center on the benefits of LSD micro-dosing.

This new research will be added onto what companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are doing to not only advance understanding of psychedelics but also to develop medicinal formulations from these substances.

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.